Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto (FMRP), Ribeirão Preto, SP, Brazil.
Universidade de São Paulo (USP), Faculdade de Medicina de Ribeirão Preto (FMRP), Ribeirão Preto, SP, Brazil; Universidade de São Paulo (USP), Faculdade de Medicina (FM), São Paulo, SP, Brazil.
Braz J Otorhinolaryngol. 2022 May-Jun;88(3):471-480. doi: 10.1016/j.bjorl.2021.03.003. Epub 2021 Apr 3.
Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual's quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment.
To review the current status of biologic treatment indications in chronic rhinosinusitis.
The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality.
Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio.
The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.
严重的、无法控制的慢性鼻-鼻窦炎伴鼻息肉会对个体的生活质量产生负面影响。因此,新的生物制剂已经出现,用于治疗慢性鼻-鼻窦炎的特定表型,改变了其治疗模式。
综述生物制剂在慢性鼻-鼻窦炎中的治疗适应证的现状。
巴西鼻科学会召集了不同的专家,根据其特点和与国家现实相关的方面提出了一个行动方案。
对于决策具有特殊意义的是识别对现有治疗方案无反应的患者亚组,并制定改善其生活质量的策略,以实现最佳的成本效益比。
生物制剂的使用是治疗更严重病例的有效选择。这一策略在未来必须得到更好的理解和改进,包括开展更多的研究和积累更多的临床经验。